Tokyo, Japan (February 15, 2017) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that its generics subsidiary, Daiichi Sankyo Espha Co., Ltd (hereinafter, Daiichi Sankyo Espha), plans to further strengthen its authorized generic (hereinafter, AG) business in Japan.

1. Daiichi Sankyo Espha AG Business
   Daiichi Sankyo Espha considers AGs to be “generic drugs that inherit trust accumulated in medical practice from the original brand drugs as an asset, and that contribute to patients and to medical practice itself.”

   In December 2014, Daiichi Sankyo Espha released an AG for Cravit® (generic name: levofloxacin) that was well-received in clinical practice.

   In the future and as medical needs increase, Daiichi Sankyo Espha expects AGs to become the standard for generics, and will aim to expand and penetrate AG products into the market, including Daiichi Sankyo origin products and from collaborations with other companies.

2. Products approved for manufacturing and marketing
   Today, Daiichi Sankyo Espha obtained approval for manufacturing and marketing for multiple AG products, including the following products:

   < Major AG products approved for manufacturing and marketing >

<table>
<thead>
<tr>
<th>Product name</th>
<th>Original brand name</th>
<th>Original brand manufacturer/distributor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olmesartan OD Tablets 5mg, 10mg, 20mg, 40mg “DSEP”</td>
<td>Olmetec® OD Tablets</td>
<td>Manufacturer: Daiichi Sankyo Co., Ltd.</td>
</tr>
<tr>
<td>Telmisartan Tablets 20mg, 40mg, 80mg “DSEP”</td>
<td>Micardis® Tablets</td>
<td>Manufacturer: Nippon Boehringer Ingelheim Co., Ltd. Distributor: Astellas Pharma Inc.</td>
</tr>
<tr>
<td>Telthia® Combination Tablets AP, BP “DSEP”</td>
<td>Micombi® Combination Tablets</td>
<td></td>
</tr>
<tr>
<td>Rosuvastatin Tablets 2.5mg, 5mg “DSEP”</td>
<td>Crestor® Tablets</td>
<td>Manufacturer: AstraZeneca K.K. Distributor: AstraZeneca K.K., Shionogi &amp; Co., Ltd.</td>
</tr>
</tbody>
</table>

   With respect to AG products approved for manufacturing and marketing this time, Daiichi Sankyo Espha plans to prepare for 2017 listings on the National Health Insurance drug price list as soon as a stable supply can be secured.
About Daiichi Sankyo Espha

Daiichi Sankyo Espha provides innovative high value-added generic drugs with formulation and devisal labeling as well as authorized generics which are manufactured from the same substances and additives that are manufactured in the same manufacturing methods in the same plant as original drugs based on the spirit of the Daiichi Sankyo Group corporate mission* of supplying pharmaceuticals to address diverse medical needs. Daiichi Sankyo Espha strives to provide pharmaceuticals that provide peace of mind for users by fulfilling the most important pharmaceutical criteria of quality, information, and stable supply while delivering the economic benefits of generics.

*Daiichi Sankyo Group corporate mission: To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs.

Daiichi Sankyo Espha Company Overview

Company name: Daiichi Sankyo Espha Co., Ltd.
Established: April 1, 2010
Business: Manufacture and sale of pharmaceuticals
Capital: 450 million yen
Representative: President Hiroto Yoshiwaka
Headquarters: 3-5-1, Nihonbashi, Honcho, Chuo-ku, Tokyo